Skip to main content
. 2019 Sep 27;10(10):1393–1399. doi: 10.1021/acsmedchemlett.9b00310

Figure 6.

Figure 6

In vivo efficacy of maytansinoid ADCs against (A) homogeneously expressing mouse Hs746T xenografts (8 mice/group), (B) heterogeneously expressing HT-29 xenografts (6 mice/group, 5 mg/kg), (C) heterogeneously expressing HT-29 xenografts (6 mice/group, 2.5 mg/kg), and (D) heterogeneously expressing OV-90 xenografts (6 mice/group).